Timing of Enoxaparin Administration After Skin Biopsy

Rationale for 24-Hour Waiting Period

The American College of Chest Physicians recommends that the first post-operative dose of low molecular weight heparin (LMWH) bridging therapy should be administered at least 24 hours after a surgical procedure to reduce bleeding risk, based on very low certainty evidence 1
The 24-hour waiting period allows for adequate surgical site hemostasis to occur before introducing anticoagulation, minimizing bleeding risk while maintaining thromboprophylactic efficacy 1

For procedures with higher bleeding risk, waiting 48-72 hours before resuming therapeutic-dose LMWH is suggested, according to the American College of Chest Physicians 1
Skin biopsies typically fall into the low-to-moderate bleeding risk category, making the 24-hour waiting period appropriate in most cases, as recommended by the American College of Chest Physicians 1
For patients at particularly high risk of venous thromboembolism (VTE) who require delayed full-dose LMWH, low-dose prophylactic LMWH can be considered during the initial 2-3 days, as suggested by the American College of Chest Physicians 1

For patients who had neuraxial anesthesia (epidural/spinal), prophylactic doses of enoxaparin (40 mg subcutaneously daily) should not be given earlier than 12 hours after the block was performed, according to guidelines from the American Journal of Obstetrics and Gynecology 2, 3
Intermediate doses of enoxaparin (40 mg subcutaneously every 12 hours) should not be given earlier than 24 hours after the block was performed, as recommended by the American Journal of Obstetrics and Gynecology 2, 3

The risk of bleeding must be weighed against the benefits of thromboprophylaxis when determining the timing of LMWH administration, as stated by The Journal of Urology 4, 5
For patients with significant intraoperative bleeding complications, the decision of when to start pharmacologic prophylaxis must be individualized, according to the American Journal of Obstetrics and Gynecology 3
In cases with high bleeding risk, mechanical prophylaxis methods (such as pneumatic compression devices) can be used until it is safe to start pharmacologic prophylaxis, as suggested by The Journal of Urology 4

For therapeutic anticoagulation, dosing of enoxaparin is typically 1 mg/kg subcutaneously every 12 hours, as recommended by the American College of Cardiology 6
Dose adjustments may be needed for patients with renal impairment, advanced age, or obesity, according to the American College of Cardiology and the American Journal of Obstetrics and Gynecology 6, 3